...MT-II to Competitive Technologies. Palatin retains rights to PT-141 bremelanotide, an active metabolite of MT-II that Competitive Technologies...
...license in a 2005 lawsuit. In 2005, the companies settled a separate dispute in which Competitive Technologies...
...treat erectile dysfunction (ED) and is in Phase I testing to treat female sexual dysfunction. Competitive Technologies...

...payment and is eligible for royalties. Homocysteine is a marker for cardiovascular and neurodegenerative diseases. Competitive Technologies...

...tests for cardiovascular diseases. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...

...counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...

...cells in vertebrates. Melanotan has sub-licensed CTT's portfolio to EPT. CTT is eligible for royalties. Competitive Technologies...

...counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...

...KG, Bristol, Tenn.) and is in Phase II testing. Palatin Technologies Inc. (PTN), Princeton, N.J. Competitive Technologies...

...will receive a license fee and is eligible for royalties. Axis-Shield plc (LSE:ASD), Dundee, U.K. Competitive Technologies...

...to CTT. ABT will pay royalties on sales of tests that use the CTT technology. Competitive Technologies...